SLC5A2 and dementia: Among nearly 75000 matched pairs, SGLT2 inhibitor use was associated with a significantly lower incidence of overall dementia compared to metformin (2.7% vs. 6.9%; adjusted HR: 0.80; 95% CI: 0.76-0.84) [12].